REGN241227C840000
- 2.05
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Regeneron Pharmaceuticals (NASDAQ:REGN) Could Easily Take On More Debt
The USA FDA has revoked the emergency use authorization for four COVID-19 antibody drugs.
On December 24, Gelonghui reported that the USA Food and Drug Administration (FDA) has revoked the emergency use authorization for four COVID-19 antibody drugs, including Eli Lilly and Co's bebtelovimab, AstraZeneca's Evusheld, GlaxoSmithKline's sotrovimab, and Regeneron's REGEN-COV. The FDA stated in a letter earlier this month that the shelf life of these drugs has expired, and due to the spread of non-susceptible variants, they have not been authorized for patient use for more than a year. According to the FDA, the four companies mentioned above do not intend to continue providing the relevant products in the USA and will notify customers and suppliers.
Express News | US FDA: Revoked Emergency Use Authorization for Regeneron's Regen-Cov as of Dec 13 - Website
If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
CCORF Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,152
Jefferies Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $950 From $1,190, Keeps Outperform Rating
Regeneron Reports Positive Results for Two Anti-coagulant Drugs
Express News | Regeneron Pharmaceuticals Inc - Regn7508 and Regn9933 Evaluated for Thrombosis Control
Regeneron to Advance Two Factor XI Antibodies Into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study
Regeneron Pharmaceuticals Shares Are Trading Higher After the Company Announced Its QUASAR Trial Investigating EYLEA HD Met Its Primary Endpoint for the Treatment of Patients With Macular Edema.
Regeneron Says Phase 3 Trial of Higher Dose Eye Drug Eylea HD Meets Primary Target
What 25 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
Express News | Bayer AG - Approximately 90% of Aflibercept 8 Mg Patients Were Extended to Every 8-Week Dosing and Maintained Their Interval Through 36 Weeks
Express News | Regeneron Pharmaceuticals Inc - Supplementary Biologics License Application Planned for Q1 2025
Express News | Regeneron Pharmaceuticals Inc - Safety Data Consistent With Known Eylea Hd and Eylea Profiles